Purine-2,6-dione-based multitarget-directed ligands inhibiting PDE/TRPA1/CHIT1 as a new approach for the treatment of COPD.

Chronic obstructive pulmonary disease (COPD) is a highly prevalent and frequently fatal respiratory disease. Current therapies for COPD do not fully target the pathogenic mechanisms of chronic inflammation, and therefore, the development of new, specific therapeutic strategies for the inflammatory process involved in the disease is urgently needed. In the present study, a focused series of novel 8-aminopurine-2,6-dione butanamides was synthesized, and their combined inhibitory activity against PDE/TRPA1/CHIT1 was evaluated. The most promising multifunctional ligands, 21, 39, and 47, exhibited anti-inflammatory and antifibrotic activities in human airway cell-based models, showing stronger effects than the reference compounds IBMX and HC-030031. Moreover, ligands 39 and 47 demonstrated more potent bronchodilatory effects ex vivo, surpassing theophylline and roflumilast. In vitro ADME-Tox data and pharmacokinetic results from in vivo studies confirmed the favorable drug-like properties of these compounds, including metabolic stability, absence of hepatotoxicity, satisfactory passive transport, and good lung penetration. Furthermore, compound 39 showed significant efficacy-comparable to that of roflumilast-after intraperitoneal (i.p.) administration in the elastase-induced emphysema murine model, which reflects key COPD symptoms and lung inflammation. This compound also reduced the level of the NLRP3 inflammasome multiprotein complex, thereby inhibiting its activation and reducing NF-κB phosphorylation. In summary, the data obtained in this study suggest that the innovative, multifunctional activity of compound 39 (as confirmed by molecular modeling studies predicting its binding mode) may represent a promising new strategy for the treatment of COPD.

• Publication year

  2025

• Venue

  Bioorganic chemistry (Print)

• Publication date

  2025-11-05

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bioorg.2025.109209PMID 41218265
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In vitro human cell-based models to study airway remodeling in asthma.

  2023cited by this paper
• Prevalence, risk factors, and mortality of COPD in young people in the USA: results from a population-based retrospective cohort

  2023cited by this paper
• Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)

  2023cited by this paper
• Application of automated machine learning in the identification of multi‐target‐directed ligands blocking PDE4B, PDE8A, and TRPA1 with potential use in the treatment of asthma and COPD

  2023cited by this paper
• Inhaled pan-phosphodiesterase inhibitors ameliorate ovalbumin-induced airway inflammation and remodeling in murine model of allergic asthma.

  2023cited by this paper
• Research Progress on TRPA1 in Diseases

  2023cited by this paper
• The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors

  2023cited by this paper
• Pan-Phosphodiesterase Inhibitors Attenuate TGF-β-Induced Pro-Fibrotic Phenotype in Alveolar Epithelial Type II Cells by Downregulating Smad-2 Phosphorylation

  2022cited by this paper
• The role of the NLRP3 inflammasome in chronic inflammation in asthma and chronic obstructive pulmonary disease

  2022cited by this paper
• In silico and in vitro ADME-Tox analysis and in vivo pharmacokinetic study of representative pan-PDE inhibitors from the group of 7,8-disubstituted derivatives of 1,3-dimethyl-7H-purine-2,6-dione.

  2022cited by this paper
• The NLRP3 inflammasome as a new target in respiratory disorders treatment

  2022cited by this paper
• An Inhibitory Function of TRPA1 Channels in TGF-β1-driven Fibroblast to Myofibroblast Differentiation

  2022cited by this paper
• Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis

  2022cited by this paper
• A TRPA1 inhibitor suppresses neurogenic inflammation and airway contraction for asthma treatment

  2021cited by this paper
• Synthesis and in vitro evaluation of anti-inflammatory, antioxidant, and anti-fibrotic effects of new 8-aminopurine-2,6-dione-based phosphodiesterase inhibitors as promising anti-asthmatic agents.

  2021cited by this paper
• New Insights into the Role of NLRP3 Inflammasome in Pathogenesis and Treatment of Chronic Obstructive Pulmonary Disease

  2021cited by this paper
• Chitinases and Chitinase-Like Proteins as Therapeutic Targets in Inflammatory Diseases, with a Special Focus on Inflammatory Bowel Diseases

  2021cited by this paper
• Tetrahydrofuran-Based Transient Receptor Potential Ankyrin 1 (TRPA1) Antagonists: Ligand-Based Discovery, Activity in a Rodent Asthma Model, and Mechanism-of-Action via Cryogenic Electron Microscopy.

  2021cited by this paper
• Chitinase-Induced Airway Hyperreactivity and Inflammation in a Mouse Model of Nonallergic Asthma

  2021cited by this paper
• Therapeutic effects of pentoxifylline on invasive pulmonary aspergillosis in immunosuppressed mice

  2021cited by this paper
• A Novel, Pan-PDE Inhibitor Exerts Anti-Fibrotic Effects in Human Lung Fibroblasts via Inhibition of TGF-β Signaling and Activation of cAMP/PKA Signaling

  2020cited by this paper
• Chitotriosidase: a marker and modulator of lung disease

  2020cited by this paper
• Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study

  2020cited by this paper
• Discovery of OATD-01, a First-in-Class Chitinase Inhibitor as Potential New Therapeutics for Idiopathic Pulmonary Fibrosis.

  2020cited by this paper
• Cinnamic acid derivatives as chemosensitising agents against DOX-treated lung cancer cells - involvement of carbonyl reductase 1.

  2020cited by this paper
• Extracellular matrix remodelling in COPD

  2020cited by this paper
• Rational Design of 2-Chloroadenine Derivatives as Highly Selective Phosphodiesterase 8A Inhibitors.

  2020cited by this paper
• Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs).

  2019cited by this paper
• Development of Dual Chitinases Inhibitors as Potential New Treatment for Respiratory System Diseases.

  2019cited by this paper
• Novel phosphodiesterases inhibitors from the group of purine-2,6-dione derivatives as potent modulators of airway smooth muscle cell remodelling.

  2019cited by this paper
• Structural Insights into Electrophile Irritant Sensing by the Human TRPA1 Channel.

  2019cited by this paper
• Phosphodiesterases as therapeutic targets for respiratory diseases.

  2019cited by this paper
• Novel amide derivatives of 1,3-dimethyl-2,6-dioxopurin-7-yl-alkylcarboxylic acids as multifunctional TRPA1 antagonists and PDE4/7 inhibitors: A new approach for the treatment of pain.

  2018cited by this paper
• PDE8: A Novel Target in Airway Smooth Muscle.

  2018cited by this paper
• Novel butanehydrazide derivatives of purine-2,6-dione as dual PDE4/7 inhibitors with potential anti-inflammatory activity: Design, synthesis and biological evaluation.

  2018cited by this paper
• Targeting Acidic Mammalian chitinase Is Effective in Animal Model of Asthma.

  2018cited by this paper
• Discovery of Selective Phosphodiesterase 1 Inhibitors with Memory Enhancing Properties.

  2017cited by this paper
• Metabolic re-patterning in COPD airway smooth muscle cells

  2017cited by this paper
• PDE8 Is Expressed in Human Airway Smooth Muscle and Selectively Regulates cAMP Signaling by &bgr;2‐Adrenergic Receptors and Adenylyl Cyclase 6

  2017cited by this paper
• Novel relaxant effects of RPL554 on guinea pig tracheal smooth muscle contractility

  2016cited by this paper
• Roflumilast: a review of its use in the treatment of COPD

  2016cited by this paper
• Arylpiperazinylalkyl derivatives of 8-amino-1,3-dimethylpurine-2,6-dione as novel multitarget 5-HT/D receptor agents with potential antipsychotic activity

  2016cited by this paper
• 2-(Isopropylamino)thieno[3,2-d]pyrimidin-4(3H)-one derivatives as selective phosphodiesterase 7 inhibitors with potent in vivo efficacy.

  2015cited by this paper
• TRPA1 as a drug target—promise and challenges

  2015cited by this paper
• New insights into mechanisms controlling the NLRP3 inflammasome and its role in lung disease.

  2014cited by this paper
• A sensory neuronal ion channel essential for airway inflammation and hyperreactivity in asthma

  2009cited by this paper
• Kinetic and structural studies of phosphodiesterase-8A and implication on the inhibitor selectivity.

  2008cited by this paper
• Methylxanthine drugs are chitinase inhibitors: investigation of inhibition and binding modes.

  2005cited by this paper
• Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram.

  2004cited by this paper
• Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity.

  2004cited by this paper
• Antiinflammatory activity of substituted 6-hydroxypyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-triones. Atypical nonsteroidal antiinflammatory agents.

  1986cited by this paper

• No citing papers are available for this paper.